Investors Back iOmx’s Focus On Tumor Immune Evasion

Developing Anti-Immune Evasion Platform

 
• By Andrew McConaghie
  
Euro symbol, Frankfurt
The consortium's funding of €65m will see iOmx's lead candidate through its Phase I development.

More from Business

More from Scrip